|
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. doi : 10.1016/S0140-6736(20)30183-5. 2. Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus. J Med Viro 2020;92:522-8. doi: 10.1002/jmv.25700. 3. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-7. doi: 10.1002/path.1570. 4. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol 2020;5:529-30. doi: 10.1016/S2468-1253(20)30084-4. 5. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020;413:116832. doi: 10.1016/j.jns.2020.116832. 6. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020;98:219-27. doi: 10.1016/j.kint.2020.04.003. 7. Hadifar S, Moghoofei M, Nematollahi S, Ramazanzadeh R, Sedighi M, Salehi-Abargouei A, et al. Epidemiology of Multidrug Resistant Uropathogenic Escherichia coli in Iran: a Systematic Review and Meta-Analysis. Jpn J Infect Dis 2017;70:19-25. doi: 10.7883/yoken.JJID.2015.652. 8. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020;10:537-40. doi: 10.1542/hpeds.2020-0123. 9. Harahsheh AS, Dahdah N, Newburger JW, Portman MA, Piram M, Tulloh R, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr 2020;222:261-2. doi: 10.1016/j.jpeds.2020.04.052. 10. Rivera-Figueroa EI, Santos R, Simpson S, Garg P. Incomplete Kawasaki Disease in a Child with Covid-19. Indian Pediatr 2020;57:680-1. doi: 10.1007/s13312-020-1900-0. 11. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43. doi: 10.1001/jamainternmed.2020.0994. 12. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020;58:1116-20. doi: 10.1515/cclm-2020-0188. 13. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res 2020;190:62. doi: 10.1016/j.thromres.2020.04.014. 14. Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost 2020;18:E1-e2. doi: 10.1111/jth.14893. 15. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimal invasive autopsies. Zhonghua Bing Li Xue Za Zhi 2020; 49:411-17. Chinese. doi: 10.3760/cma.j.cn112151-20200312-00193. 16. Choi G, Schultz MJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004;24:786-9. doi: 10.1183/09031936.04.00140703. 17. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X. 18. Monteleone G, Sarzi-Puttini PC, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol 2020;2:e255-e6. doi: 10.1016/S2665-9913(20)30092-8. 19. Li Z, Yin M, Zhang H, Ni W, Pierce RW, Zhou HJ, et al. BMX represses thrombin-PAR1–mediated endothelial permeability and vascular leakage during early sepsis. Circ Res 2020;126:471-85. doi: 10.1161/CIRCRESAHA.119.315769. 20. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol 2020;214:108393. doi: 10.1016/j.clim.2020.108393. 21. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417-8. doi: 10.1016/S0140-6736(20)30937-5. 22. Perdomo J, Leung HHL, Ahmadi Z, Yan F, Chong JJH, Passam FH, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun 2019;10:1322. doi: 10.1038/s41467-019-09160-7. 23. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 2020;136:489-500. doi: 10.1182/blood.2020006520. 24. He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep 2021;11:1830. doi: 10.1038/s41598-021-81300-w. 25. Zhang X, Liu ZQ, Zhang W, Xu Q. A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression. Int J Clinl Exp Med 2014;7:2395-401. 26. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy. Crit Care 2020;24:1-8. doi: 10.1186/s13054-020-03077-0. 27. Gandhi A, Görlinger K. Coagulopathy in COVID-19: Connecting the dots together. J Card Crit Care TSS 2020;4:47-50. doi:10.1055/s-0040-1712739. 28. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemos 2020;18:844-7. doi: 10.1111/jth.14768. 29. Zhuang Q, Zeng Y, Shi Y. Coagulopathy correlates with outcomes in patients with community- acquired pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2014;37:406-10. 30. Terpos E, Ntanasis‐Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834-47. doi: 10.1002/ajh.25829.
|
